Breast Cancer Drug Discoveries: what the future holds

Report Summary

In 2010, almost 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are required to increase survival and delay disease progression.
In 2010, almost 50% of breast cancer sales were due to three branded targeted therapies. With a large unmet clinical need, further agents are required to increase survival and delay disease progression.

Unique breast cancer market share, sales forecasts by launched and Phase III products to 2017
A comprehensive and critical examination and scoring of 72 major breast cancer treatmentsr
Comprehensive market assessment of therapeutic approaches, company share, portfolios and prospects

Breast Cancer Therapy Sales Forecast 2010 - 2017

'What’s the story behind this chart?'

Buy Now:http://www.reportsnreports.com/reports/125092-breast-cancer-drug-discoveries-what-the-future-holds.html

The changing competitive landscape

By 2017, Espicom forecasts a modest increase in the number of players in the market-place compared to 2010, with Roche, and GlaxoSmithKline to a lesser extent, triumphing with targeted therapies directed against the specific subset of BC patients with HER2-positive disease. AstraZeneca, Novartis and Pfizer will face widespread generic competition for their hormonal therapies, leading to a loss of market share. Similarly, Sanofi and Eli Lilly will face declining sales for their chemotherapies.

The market in 2010.

In recent years, more effective treatments have decreased mortality and improved survival rates, resulting in a longer duration of therapy for an increased patient population. In the US, five-year relative survival rates have improved from 63% in the early 1960s to 90% in recent years, while in England, rates for women diagnosed with BC in 2001-2006 reached 82%, compared to 52% 1971-1975. This report estimates that sales of leading brands achieved sales of US$12.7 billion in 2010, with growth due to expanding sales for a number of existing treatments rather than the launch of new products. Sales were split between chemotherapies, hormonal therapies and novel molecular targeted therapies, with the majority of these agents used in combination.

And 2017: how things might change Hormonal therapiesr
The aromatase inhibitors will suffer from patent expiries in all major markets by 2012, and the report expects significant generic competition and sales for this group to decline by over 92% from US$3.4 billion in 2010, to just US$259 million in 2017. With widespread generic versions of the leading selective oestrogen receptor modulator, tamoxifen, the overall market share of branded hormonal therapies will decline as sales fall from US$4 billion to US$1.4 billion, a drop of 65%. These declines will be tempered by the relative success of AstraZeneca’s Faslodex.

Browse All: http://www.reportsnreports.com/market-research/pharmaceuticals/

Related Reports:

Toshiba Medical Systems Medical Device Company Intelligence Report - http://www.reportsnreports.com/reports/53391-toshiba-medical-systems-medical-device-company-intelligence-repor.html

Smiths Medical Medical Device Company Intelligence Report - http://www.reportsnreports.com/reports/53383-smiths-medical-medical-device-company-intelligence-report.html